Evidence map›Paper›PMID 30478492›Full record

SynthesisInternational journal of clinical pharmacy2018

Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis.

Cristina Trigo-Vicente, Vicente Gimeno-Ballester, Santiago García-López, Alejandro López-Del Val

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical pharmacy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 5 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Emerging role of Janus kinase inhibitors in ulcerative colitis management.World journal of gastrointestinal pharmacology and therapeutics · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Efficacy of JAK inhibitors in Ulcerative Colitis.Journal of Crohn's & colitis · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Cristina Trigo-VicentePharmacy Department, C.R.P. Nuestra Señora del Pilar, Avda Duquesa Villahermosa, 66, 50009, Zaragoza, Spain. cristinatrigo86@gmail.com.ORCID http://orcid.org/0000-0001-5238-9052
Vicente Gimeno-BallesterPharmacy Department, Hospital Universitario Miguel Servet, Paseo Isabel La Católica, 1-3, 50009, Zaragoza, Spain.
Santiago García-LópezGastroenterology Department, Hospital Universitario Miguel Servet, Paseo Isabel La Católica, 1-3, 50009, Zaragoza, Spain.
Alejandro López-Del ValHealth Science, Universidad San Jorge, Autovía Mudéjar, km. 299, 50830, Villanueva de Gállego, Zaragoza, Spain.
Hospital Universitario Miguel Servet · ESUniversidad de Zaragoza · ESUniversidad San Jorge · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Biological drugs for moderate-to-severe ulcerative colitis have changed the therapeutic perspective, while small-molecule inhibitors and new promising drugs suggest new options. Aim Assess comparative efficacy and safety of biological and new small oral drugs: commercialized and under-investigation ones for patients naïve to biological drugs. Methods A systematic review was conducted to identify the randomized clinical trials phase 2 or 3, in adults with moderate-to-severe ulcerative colitis treated with biological drugs (infliximab, adalimumab, golimumab, vedolizumab and etrolizumab) or new oral small molecules (tofacitinib and ozanimod) as first line. A Bayesian network metaanalysis was performed to inform comparative efficacy and safety of different treatments. Efficacy outcomes were clinical remission, clinical response and mucosal healing for induction therapy and clinical remission, mucosal healing and sustained clinical remission for maintenance therapy. Safety was assessed with serious adverse events and rates of infections. Results 14 references were included for network meta-analysis. For induction therapy, infliximab was the best drug for induction of clinical response and remission, while ozanimod showed to be the best for induction of mucosal healing. Tofacitinib had the highest rate of maintaining clinical remission. All treatments were similar for serious adverse events, and vedolizumab and tofacitinib had the highest rates of infections. Conclusion This network meta-analysis suggests infliximab may be the best therapeutic option for moderate-to-severe ulcerative colitis. Vedolizumab seems to have better outcomes in maintenance than in induction therapy and it appears superior to golimumab and adalimumab. Tofacitinib, ozanimod and etrolizumab show encouraging results.

Indexed as

Antibodies, Monoclonal, HumanizedAnti-Ulcer AgentsBiological ProductsColitis, UlcerativeHumansRandomized Controlled Trials as TopicSmall Molecule LibrariesAntibodies, Monoclonal, HumanizedAnti-Ulcer AgentsBiological ProductsSmall Molecule LibrariesBiological drugsNetwork meta-analysisNew small oral moleculesUlcerative colitis

Identifiers

PMID30478492
OpenAlexW2903231225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.